Back to top

messenger-rna: Archive

Zacks Equity Research

Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission

Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.

PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

GSKPositive Net Change VRTXPositive Net Change MRNANegative Net Change CVACPositive Net Change

Zacks Equity Research

Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

PFEPositive Net Change ALKSPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron

Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.

AZNPositive Net Change PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Up on Plans to Get Omicron Booster Ready in 2022

Moderna (MRNA) plans to begin clinical development of its Omicron-specific variant vaccine early in 2022 and expects to make it available for the public in the fall of 2022.

REGNNegative Net Change PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change